NHS Framework for the Midlands and East, Branded Medicines – Tranche B plus Cytokine Modulators and other Monoclonal Antibodies.
key details
| Status | complete |
|---|---|
| Category (CPV) | 33600000 |
| Procedure | open |
| OCID | ocds-h6vhtk-029565 |
Awards (37)
This procurement was awarded to 37 suppliers. Values shown are per-award; the notice total is ·.
| Supplier | Value | Date | Status |
|---|---|---|---|
| Accord-UK Ltd shared | · | · | active |
| Amgen Ltd shared | · | · | active |
| AstraZeneca shared | · | · | active |
| Aventis Pharma ltd t/a Sanofi shared | · | · | active |
| Bayer Ltd shared | · | · | active |
| Biogen shared | · | · | active |
| Bristol Myers Squibb shared | · | · | active |
| Celltrion Healthcare United Kingdom Limited shared | · | · | active |
| CST Pharma Limited shared | · | · | active |
| Daiichi Sankyo UK Ltd shared | · | · | active |
| Day Lewis Medical Ltd shared | · | · | active |
| Dr.Reddy's Laboratories (UK) Limited shared | · | · | active |
| Eli Lilly and Company Ltd shared | · | · | active |
| Ferring Pharmaceuticals Ltd shared | · | · | active |
| Gedeon Richter UK Ltd shared | · | · | active |
| Gilead Sciences Limited shared | · | · | active |
| Ipsen shared | · | · | active |
| Janssen-Cilag Ltd shared | · | · | active |
| LEO Pharma shared | · | · | active |
| Merck Serono Limited shared | · | · | active |
| Merck Sharp and Dohme (MSD) shared | · | · | active |
| Merck Sharpe and Dohme (UK) Limited shared | · | · | active |
| Mylan shared | · | · | active |
| Napp Pharmaceuticals Ltd shared | · | · | active |
| Novartis Pharmaceuticals UK Ltd shared | · | · | active |
| Novo Nordisk shared | · | · | active |
| Pfizer Ltd shared | · | · | active |
| Roche Products Ltd shared | · | · | active |
| ROVI Biotech Ltd shared | · | · | active |
| Sandoz Ltd shared | · | · | active |
| Sobi (Swedish Orphan Biovitrum Ltd) shared | · | · | active |
| Takeda UK Ltd shared | · | · | active |
| Techdow Pharma England Ltd shared | · | · | active |
| Teva UK Limited shared | · | · | active |
| Thornton and Ross Ltd shared | · | · | active |
| UCB Pharma Ltd shared | · | · | active |
| UL Global Pharma shared | · | · | active |
description
CM/PHR/20/5591/01 - Midlands and East, Branded Medicines – Tranche B. Period of framework: 1 March 2021 to 28 February 2023 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 24 monthsCM/PHR/20/5591/02 - Midlands and East Branded Medicines – Annual Tranche, Cytokine Modulators, other monoclonal antibodies Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma. Period of framework: 1 March 2021 to 28 February 2022 with an option to extend (at the Authority’s discretion) for a period or periods up to a total of 12 monthsCM/PHR/20/5591/03 – Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to Pan London. Period of framework: 1 March 2021 to 31 August 2021CM/PHR/20/5591/04 – Supply of Interleukin Inhibitors, JAK Inhibitors and medicines for Migraine and Asthma to South of England. Period of framework: 1 March 2021 to 31 August 2021
notice history
1 notice published against this procurement.
| Published | Type | Regime | Notice |
|---|---|---|---|
| 23 Feb 2021 | Contract award notice (F03) | Earlier regulations | 003581-2021 |
more from The NHS Commissioning Board (operating under the name of NHS England)
- Implementation of GP referral pathway to NHS CPCS · £1,700,000 · 12 May 2022
- NHS England and NHS Improvement - Independent Clinical Reviews into Deaths in Custody – South East Health & Justice, Detained Estates · 29 Apr 2022
- Provision of Benchmarking Performance Against the Learning Disability Improvement Standards for NHS Trusts · £800,000 · 18 Mar 2022
- PMO Support for the Cancer Healthcare and AI in Health and Care Programmes · £2,000,000 · 3 Mar 2022
- NHS Framework for the North of England, Branded Medicine · £863,999,552 · 1 Mar 2022
- NHS Framework for Midlands and East, Branded Medicines – Tranche A and Annual · £216,078,796 · 22 Feb 2022
- NHS National Generic Pharmaceuticals Wave 13 · £1,637,875,080 · 14 Jan 2022
- Targeted Lung Health Check Programme: External Quality Assurance of Radiologists · £800,000 · 22 Dec 2021
all contracts from this buyer →
similar contracts awarded
Other awarded contracts in the same category. Useful for seeing who normally wins this kind of work, and at what value.
- Radiopharmaceutical Products - Poltech · The Christie NHS Foundation Trust · £39,000
- NHS Branded Medicines - Tranche B - London & South of England - 1 September 2026 · NHS England · £592,363,416
- NHS National Generics Pharmaceuticals - Supply Chain Resilience · NHS England · £52,447,296
- Generic, Branded Generic & Proprietary Medicinal Products - Group 18 · Regional Business Services Organisation, Procurement and Logistics Service · £1,800,000,000
- Generic Drugs – Injections/Infusions 2 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £6,535,850
- Transitional Drugs 7 · NHS Wales Shared Services Partnership-Procurement Services (hosted by Velindre University NHS Trust) · £53,566,932
- NP90726m Vedolizumab (Entyvio®) · The Common Services Agency (more commonly known as Public Services Delivery Scotland) (PSD Scotland) · £47,898,609
- Combined Needles and Syringes Lot 1 · Secretary of State for Health and Social Care acting as part of the Crown through UK Health Security Agency · £15,264,000
source
Published on Find a Tender. Contact details for named individuals are not reproduced on this site.